Medical Chronicle November/December 2013 | Page 66

NEW PRODUCTS/DEVELOPMENTS Malaria test Powerful combination to beat hypertension to improve diagnosis Pharma Dynamics has announced the launch of Bilocor Co (bisoprolol hydrochlorothiazide), a line extension to their leading beta blocker Bilocor. Bilocor Co is a low-dose multimechanism agent that combines the cardioselective beta blocker bisoprolol fumarate with hydrochlorothiazide. It is indicated for the treatment of hypertension in patients who have been stabilised on the individual components given in the same proportions. The product is available in three different strengths at an SEP (excl. VAT) of R65 for 2.5/6.25mg, R69 for the 5/6.25mg and R74 for 10/6.25mg, all strengths are packed in 30s. It offers patients savings of up to 44% vs the originator, making the management of hypertension even more affordable. The package insert is available on request from Karin Bissolati at 021-707-7000 or email [email protected] Award-winning Australian healthcare company, Atomo Diagnostics, who recently launched the innovative all in one rapid HIV test AtomoRapid HIV, are set to introduce its malaria counterpart to the continent at the 6th MIM Pan-African Malaria Conference in Durban this month. AtomoRapid Malaria, which is ideal for both professional and self-test applications, will enable quick and reliable diagnosis of malaria in the field. AtomoRapid™ Malaria will be manufactured in South Africa with production taking place at a new ISO 13485-certified facility. This makes it not only the world’s most user friendly rapid Malaria test, but an African-made test that can be exported to the benefit of the rest of the world. “The Atomo team has been working hard towards making AtomoRapid HIV and AtomoRapid Malaria available to the market at a competitive price and the response we have received so far has been fantastic we now look forward to collaborating with leading organisations to change the Rapid testing landscape,” said John Kelly, the CEO & Founder of Atomo Diagnostics. AtomoRapid™ Malaria will be available to customers in the coming months. Acne can have a significant impact on a pateint’s quality of life. He or she may feel embarrassed, angry or experience other psychological disturbances. Aspen and Stiefel, a GSK company, have announced the launch of Clindoxyl® once-daily gel for the treatment of mild to moderate acne vulgaris in adults and adolescents. It is an effective combination of clindamycin 1% and benzoyl peroxide 5%, which results in: • Rapid onset of action in one week References available on request. • Provides efficiency and synergy • Reduces clindamyci n resistance • Has favourable tolerability profile. For more information, contact Rowena Naidoo on 011-239-6069 or email [email protected] References available on request. Dräger’s new head office Claudia Dräger, Mr Rob Brown, Marius Fourie - (Dräger SA MD) and Michael Karsta Dräger in South Africa will consolidate its two main subsidiaries Safety and Medical into one head office. The new office will be situated in the Waterfall Commercial District just north of Sandton. The new office is expected to be opened October 2014. The Dräger Group is headquartered in Lübeck, Germany. Dräger offers its customers anaesthesia Treating acne changes lives workstations, medical ventilation, patient monitoring as well as neonatal care for premature babies and neonates. With ceiling supply units, IT solutions for the OR, and gas management systems the company is at the customer’s side throughout the entire hospital. The company celebrated the 10th anniversary of the South African Medical subsidiary this year. 66 MEDICAL CHRONICLE NOVEMBER/DECEMBER 2013 Synalar range of products back in stock Glenmark Pharmaceuticals is pleased to announce that all the Synalar range of products are now available. Products that were affected by the sourcing of raw material API were Synalar cream and ointment; Synalar-N ointment and Synalar-C cream. Synalar range is indicated for steroidresponsive dermatoses with or without secondary infections. Its active ingredient fluocinolone acetonide is a medium potency corticosteroid. Synalar-C cream and ointment in addition to the corticosteroid, contains Clioquinol a broadspectrum antibacterial and antifungal agent.